Related Experiment Videos
Cancer therapy with DNA-based vaccines
1Department of Microbiology and Immunology (M/C 790), University of Illinois College of Medicine, Chicago, IL 60612, USA. epcohen@uic.edu
Immunology Letters
|September 21, 2000
Summary
This study developed effective DNA-based cancer vaccines in mice by transfecting tumor DNA into modified fibroblasts. These novel vaccines significantly extended survival in tumor-bearing mice, demonstrating therapeutic potential.
Area of Science:
- Immunology
- Oncology
- Genetics
Background:
- Tumor-associated antigens (TAAs) are often weakly immunogenic.
- Antigen-presenting cells can enhance TAA immunogenicity.
- DNA-based vaccines offer a novel approach to cancer immunotherapy.
Purpose of the Study:
- To develop and evaluate the efficacy of DNA-based cancer vaccines.
- To investigate the immunotherapeutic potential of transfected fibroblasts against tumors.
- To determine the immune mechanisms underlying the vaccine's effectiveness.
Main Methods:
- Genomic DNA from breast cancer cells was transfected into modified mouse fibroblasts.
- Fibroblasts were engineered to express allogeneic MHC determinants and secrete IL-2.
- Transfected cells were used to immunize tumor-bearing mice, and survival rates were analyzed.
- Immune responses were assessed, including T-cell mediation and tumor specificity.
Main Results:
- DNA-transfected fibroblasts demonstrated significant therapeutic efficacy in mice with breast adenocarcinoma.
- Similar survival benefits were observed in mice treated for melanoma using syngeneic transfected cells.
- The induced anti-tumor immunity was mediated by CD8(+) T cells and was specific to the tumor type.
Conclusions:
- Genomic DNA transfection into engineered fibroblasts can create effective cancer vaccines.
- This approach holds promise for developing targeted immunotherapies for various cancers.
- The study highlights the potential of manipulating antigen-presenting cells for enhanced anti-tumor immune responses.